Safety and Effectiveness of SB2 (Infliximab Biosimilar) in Adult Patients with Immune-Mediated Inflammatory Diseases: A Post-Marketing Surveillance in Korea
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Safety and Effectiveness of SB2 (Infliximab Biosimilar) in Adult Patients with Immune-Mediated Inflammatory Diseases: A Post-Marketing Surveillance in Korea ; volume:40 ; number:3 ; day:10 ; month:1 ; year:2023 ; pages:1047-1061 ; date:3.2023
Advances in therapy ; 40, Heft 3 (10.1.2023), 1047-1061, 3.2023
- Creator
-
Kim, Dong W.
Lee, Yousun
Kim, Geuntae
Kim, Sang H.
Cho, Dae H.
Choi, Jeongmin
Kwon, Yong H.
Park, Younjin
Choi, Wooree
Park, Dong I.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s12325-022-02404-x
- URN
-
urn:nbn:de:101:1-2408192201386.994167071792
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 14.08.2025, 11:01 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kim, Dong W.
- Lee, Yousun
- Kim, Geuntae
- Kim, Sang H.
- Cho, Dae H.
- Choi, Jeongmin
- Kwon, Yong H.
- Park, Younjin
- Choi, Wooree
- Park, Dong I.
- SpringerLink (Online service)
Other Objects (12)
PF-06438179/GP1111: An Infliximab Biosimilar
Exposure to Infliximab During Pregnancy: Post-Marketing Experience
Safety and Effectiveness of Trastuzumab Biosimilar SB3 in Korean Patients, a Post-Marketing Surveillance Study
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar
Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases
Safety and Effectiveness of Etanercept Biosimilar SB4 for Rheumatic Diseases in South Korea: Real-World Post-marketing Surveillance Data
Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade® (Infliximab)
Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project
Real-World Safety and Effectiveness of Infliximab in 255 Patients with Intestinal, Neurological, and Vascular Behçet’s Disease: A Post-Marketing Surveillance
Analytical and Functional Similarity Assessment of ABP 710, a Biosimilar to Infliximab Reference Product
Post-marketing safety surveillance and re-evaluation of Xueshuantong injection
PF-06438179/GP1111: An Infliximab Biosimilar
Exposure to Infliximab During Pregnancy: Post-Marketing Experience
Safety and Effectiveness of Trastuzumab Biosimilar SB3 in Korean Patients, a Post-Marketing Surveillance Study
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar
Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases
Safety and Effectiveness of Etanercept Biosimilar SB4 for Rheumatic Diseases in South Korea: Real-World Post-marketing Surveillance Data
Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade® (Infliximab)
Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project
Real-World Safety and Effectiveness of Infliximab in 255 Patients with Intestinal, Neurological, and Vascular Behçet’s Disease: A Post-Marketing Surveillance
Analytical and Functional Similarity Assessment of ABP 710, a Biosimilar to Infliximab Reference Product
Post-marketing safety surveillance and re-evaluation of Xueshuantong injection
PF-06438179/GP1111: An Infliximab Biosimilar
Exposure to Infliximab During Pregnancy: Post-Marketing Experience
Safety and Effectiveness of Trastuzumab Biosimilar SB3 in Korean Patients, a Post-Marketing Surveillance Study
Correction to: PF-06438179/GP1111: An Infliximab Biosimilar
Crystal Structures of PF-06438179/GP1111, an Infliximab Biosimilar
Review of Adalimumab Biosimilar SB5 in Immune-Mediated Inflammatory Diseases
Safety and Effectiveness of Etanercept Biosimilar SB4 for Rheumatic Diseases in South Korea: Real-World Post-marketing Surveillance Data
Nonclinical Evaluation of PF-06438179: A Potential Biosimilar to Remicade® (Infliximab)
Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project
Real-World Safety and Effectiveness of Infliximab in 255 Patients with Intestinal, Neurological, and Vascular Behçet’s Disease: A Post-Marketing Surveillance
Analytical and Functional Similarity Assessment of ABP 710, a Biosimilar to Infliximab Reference Product